Charles River Laboratories International (NYS: CRL) reported earnings on Aug. 7. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Charles River Laboratories International met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped slightly and GAAP earnings per share was unchanged.
Margins contracted across the board.
Charles River Laboratories International notched revenue of $284.7 million. The 11 analysts polled by S&P Capital IQ predicted a top line of $285.4 million on the same basis. GAAP reported sales were 1.2% lower than the prior-year quarter's $288.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.75. The 17 earnings estimates compiled by S&P Capital IQ forecast $0.66 per share. GAAP EPS of $0.63 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 36.4%, 50 basis points worse than the prior-year quarter. Operating margin was 17.3%, 120 basis points worse than the prior-year quarter. Net margin was 10.7%, 50 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $283.0 million. On the bottom line, the average EPS estimate is $0.65.
Next year's average estimate for revenue is $1.15 billion. The average EPS estimate is $2.68.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Charles River Laboratories International is hold, with an average price target of $38.83.
Add Charles River Laboratories International to My Watchlist.
The article Charles River Laboratories International Beats Analyst Estimates on EPS originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.